<SEC-DOCUMENT>0001593968-21-001695.txt : 20210624
<SEC-HEADER>0001593968-21-001695.hdr.sgml : 20210624
<ACCEPTANCE-DATETIME>20210624201741
ACCESSION NUMBER:		0001593968-21-001695
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210528
FILED AS OF DATE:		20210624
DATE AS OF CHANGE:		20210624

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			RIEFLIN WILLIAM JL
		CENTRAL INDEX KEY:			0001182471

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38997
		FILM NUMBER:		211044333

	MAIL ADDRESS:	
		STREET 1:		NGM BIOPHARMACEUTICALS, INC.
		STREET 2:		333 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RAPT Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001673772
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473313701
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 489-9000

	MAIL ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLX Bio, Inc.
		DATE OF NAME CHANGE:	20160504
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>primary_01.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2021-05-28</periodOfReport>

    <issuer>
        <issuerCik>0001673772</issuerCik>
        <issuerName>RAPT Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>RAPT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001182471</rptOwnerCik>
            <rptOwnerName>RIEFLIN WILLIAM JL</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O RAPT THERAPEUTICS, INC.,</rptOwnerStreet1>
            <rptOwnerStreet2>561 ECCLES AVENUE</rptOwnerStreet2>
            <rptOwnerCity>SOUTH SAN FRANCISCO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94080</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>19.30</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2021-05-28</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>7500</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2031-05-27</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>7500</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>7500</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The Option shall vest on the earlier of (i) May 28, 2022, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2022, subject to the Reporting Person's continuous service through each applicable vesting date.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Rodney Young, Attorney-in-Fact for William Rieflin</signatureName>
        <signatureDate>2021-06-24</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>rieflin_poa.txt
<DESCRIPTION>EX-24 DOCUMENT
<TEXT>
POWER OF ATTORNEY
       Know all by these presents, that the undersigned hereby constitutes
and appoints each of BRIAN WONG, RODNEY YOUNG, JOEL FERNANDES, and MICHAEL
TENTA, signing individually, the undersigned's true and lawful
attorneys-in-fact and agents to:
(1)	execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer, director or beneficial owner of more than 10% of a
registered class of securities of RAPT THERAPEUTICS, INC. (the "Company"),
Forms 3, 4 and 5 (including any amendments thereto) in accordance with
Section 16(a) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act") and the rules thereunder and a Form ID, Uniform Application
for Access Codes to File on EDGAR;
(2)	do and perform any and all acts for and on behalf of the undersigned
that may be necessary or desirable to execute such Forms 3, 4 or 5 or Form
ID (including any amendments thereto) and timely file such forms with the
United States Securities and Exchange Commission and any stock exchange or
similar authority; and
(3)	take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of
benefit, in the best interest of, or legally required by, the undersigned,
it being understood that the documents executed by such attorney-in-fact on
behalf of the undersigned pursuant to this Power of Attorney shall be in
such form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's discretion.
       The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any
of the rights and powers herein granted, as fully to all intents and
purposes as the undersigned might or could do if personally present, with
full power of substitution or revocation, hereby ratifying and confirming
all that such attorney-in-fact, or such attorney-in-fact's substitute or
substitutes, shall lawfully do or cause to be done by virtue of this power
of attorney and the rights and powers herein granted. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such
capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Exchange Act.
       This Power of Attorney shall remain in full force and effect until
the earliest to occur of (a) the undersigned is no longer required to file
Forms 3, 4 and 5 with respect to the undersigned's holdings of and
transactions in securities issued by the Company, (b) revocation by the
undersigned in a signed writing delivered to the foregoing
attorneys-in-fact or (c) as to any attorney-in-fact individually, until
such attorney-in-fact is no longer employed by the Company or Cooley LLP.
       IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of April 16, 2021.

/s/ William Rieflin
William Rieflin




</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
